Characteristics of Included Studies

Medication Time

Doses of Medication

Number of Patients

Study

Year

N

Clinical Trail Setting

Fondaparinux

LMWH

Fondaparinux

LMWH

Fondaparinux

LMWH

OASIS-5

2006

20078

Multicentered, double blind RCT

8 Day

2 - 8 Day

2.5 mg qd

1 mg/kg bid

10021

10057

PENTUA

2004

459

Multicentered, double blind RCT

3 - 7 Day

3 - 7 Day

2.5 mg qd

1 mg/kg bid

229

230

Yan

2011

300

prospective, open-label, and single center study, RCT

4 Day

4 Day

2.5 mg qd

0.01 ml/kg q12

150

150